On August 28, 2017 Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, reported posters on tucatinib in multiple tumor types will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2017 Congress being held September 8-12, 2017 in Madrid, Spain (Press release, Cascadian Therapeutics, AUG 28, 2017, View Source [SID1234520320]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Please visit the Cascadian Therapeutics booth #270 at ESMO (Free ESMO Whitepaper) for more information about tucatinib, the Company’s lead product candidate for the treatment of HER2-positive breast cancer being evaluated in a global, randomized pivotal trial known as HER2CLIMB. Abstracts will be available online at View Source Poster presentations will be available at www.cascadianrx.com as of the presentation date.
Poster Presentations
Title: Progression-free survival and site of first progression in HER2-positive metastatic breast cancer patients with or without brain metastases: A pooled analysis of tucatinib phase I studies
Date: Monday, September 11, 2017, 1:15-2:15 p.m. CEST
Poster: 264, Location: Hall 8
Title: Tucatinib, a HER2 selective kinase inhibitor, is active in patient derived xenograft (PDX) models of HER2-amplified colorectal, esophageal and gastric cancers
Date: Monday, September 11, 2017, 1:15-2:15 p.m. CEST
Poster: 1639, Location: Hall 8
Title: Evaluation of drug-drug interactions (DDI) between tucatinib and capecitabine in patients with advanced HER2-positive metastatic breast cancer from a phase 1b study
Date: Monday, September 11, 2017, 1:15-2:15 p.m. CEST
Poster: 297, Location: Hall 8
About Tucatinib
Tucatinib is an investigational, orally bioavailable, potent tyrosine kinase inhibitor that is highly selective for HER2 without inhibition of the EGFR. Inhibition of EGFR has been associated with clinically relevant toxicities, including skin rash and diarrhea. Tucatinib has shown activity as a single agent and in combination with both chemotherapy and other HER2 directed agents such as trastuzumab and T-DM1.1,2 Studies of tucatinib in these combinations have shown activity both systemically and in brain metastases. HER2 is a growth factor receptor that is overexpressed in multiple cancers, including breast, ovarian and gastric cancers. HER2 mediates cell growth, differentiation and survival. Tumors that overexpress HER2 (HER2-positive) are more aggressive and historically have been associated with poor overall survival, compared with HER2-negative cancers.